|

Human Clinical Trials
Below we have included just a few of the many Human clinical trials conducted on MSM. Many clinical trials and studies have also been conducted on animals which provide convincing
evidence that MSM is a critical component which supports healthy joints and joint function. NOTE: The most effective results with MSM are reported amoung professionals and customers
when taken in conjuction with a high quality and diverse antioxidant. Suvida Maritime Pine PLUS and Ultra Pine Plus formulations are the most effective and diverse antioxidant blends available.
For the most effective and noteable joint relief, try taking one of these powerful antioxidant blends in combination with MSM.
Radboud University - Netherlands.
Engelke UF, Tangerman A, Willemsen MA, et al. Dimethyl sulfone [MSM] in human cerebrospinal fluid and blood plasma confirmed by one-dimensional (1)H and two-dimensional (1)H-(13)C NMR. NMR Bio Med 2005;18:33l-6.
Radboud University Nijmegen Medical Centre, Laboratory of Pediatrics and Neurology, L-6500 HB Nijmegen, The Netherlands. [Abstract on PubMed]
(1)H-NMR spectroscopy at 500 MHz was used to confirm that a previously unidentified singlet resonance at 3.14 ppm in the spectra of cerebrospinal fluid and plasma samples corresponds to
dimethyl sulfone (DMSO(2)). A triple resonance inverse cryogenic NMR probe, with pre-amplifier and the RF-coils cooled to low temperature, was used to obtain an (1)H-(13)C HSQC spectrum
of CSF containing 8 microM (753 ng/ml) DMSO(2). The (1)H-(13)C correlation signal for DMSO(2) was assigned by comparison with the spectrum from an authentic reference sample. In plasma and
CSF from healthy controls, the concentration of DMSO(2) ranged between 0 and 25 micromol/l. The concentration of DMSO(2) in plasma from three of four patients with severe methionine
adenosyltransferase I/III (MAT I/III) deficiency was about twice the maximum observed for controls. Thus, DMSO(2) occurs as a regular metabolite at low micromolar concentrations in
cerebrospinal fluid and plasma. It derives from dietary sources, from intestinal bacterial metabolism and from human endogenous methanethiol metabolism. Copyright (c) 2005 John Wiley & Sons, Ltd.
Tempe AZ, USA
Kim LS, Axelrod LJ, Howard P, Buratovich N, Waters RF. Efficacy of methylsulfonyl-methane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial.
Osteoarthritis and Cartilage 2006;14:286-94. Southwest College Research Institute, Southwest College of Naturopathic Medicine & Health Sciences, Tempe, AZ, USA. [Abstract on PubMed]
In 2004, Kim et al conducted a randomized, double-blind, placebo-controlled clinical trial to evaluate the effects of distilled MSM on mild to moderate osteoarthritis of the knee.
Participants received 3,000 mg twice daily of either placebo or MSM (OptiMSM, Bergstrom Nutrition, Vancouver, WA)) for 12 weeks. Patients were evaluated using standardized clinical
efficacy scales as well as for several secondary endpoints, adverse events, and clinical laboratory markers. Compared to placebo, those taking MSM had statistically significant
reductions in pain and in difficulty performing activities of daily living. Statistically significant reductions in serum homocysteine (a risk factor for cardiovascular disease) and
urinary malondialdehyde (a marker of oxidative stress) were also observed. There were no significant adverse events in the study.
Multi-Centered Trial
Barrager E, Veltmann JR, Schauss AG, Schiller RN. A multi-centered, open label trial on the safety and efficacy of methylsulfonylmethane in the treatment of seasonal allergic rhinitis.
J Altern Complement Med 2002;8:167-74.
In a open-label study of 55 patients with seasonal allergic rhinitis (SAR; hayfever), MSM at 2600mg/day significantly reduced upper and total respiratory symptoms within 7 days; lower
respiratory symptoms were significantly improved from baseline by week 3. No significant changes were observed in plasma IgE or histamine levels. Few side effects were associated with the use
of MSM and no patient dropped out of the study due to adverse reactions. Energy levels increased significantly by day 14. The results suggest that MSM may be an efficacious in reducing symptoms
associated with SAR.
Blum JM, Blum RI. The effect of methylsulfonylmethane (MSM) in the control of snoring. Integrative Medicine 2004;3(6)24-30.
Childs SJ. Dimethyl sulfone (DMSO2) in the treatment of interstitial cystitis. Urol Clin North Am 1994;21:85-8.
Dr. Childs presents six case studies on the use of intravesicular MSM for interstitial cystitis in patients who were refractory to previous therapy.
Lawrence RM. Methylsulfonylmethane (M.S.M.) A double-blind study of its use in degenerative arthritis. Int J Anti-Aging Med 1998;1(1):50 [abstract].
In this abstract, Lawrence presented data on a "preliminary study" in which patients suffering from degenerative arthritis were treated with either 2,250 mg per day of MSM (Adaptin, no
manufacturer specified) or placebo for an unspecified length of time. Sixteen patients were reportedly enrolled in the study. Eight received MSM and six received placebo. The author does not
indicate what treatment, if any, was administered to the two remaining patients. Lawrence reported "a better than 80 percent control of pain within six weeks of beginning the study." The title
of the abstract indicates that a double-blind protocol was followed.
** This product is not intended to diagnose, treat, cure, or prevent any disease and is not intended to replace any FDA approved or physician recommended treatments.
|